Cargando…

Expansion of regulatory T cells by CD28 superagonistic antibodies attenuates neurodegeneration in A53T-α-synuclein Parkinson’s disease mice

BACKGROUND: Regulatory CD4(+)CD25(+)FoxP3(+) T cells (Treg) are a subgroup of T lymphocytes involved in maintaining immune balance. Disturbance of Treg number and impaired suppressive function of Treg correlate with Parkinson’s disease severity. Superagonistic anti-CD28 monoclonal antibodies (CD28SA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Badr, Mohammad, McFleder, Rhonda L., Wu, Jingjing, Knorr, Susanne, Koprich, James B., Hünig, Thomas, Brotchie, Jonathan M., Volkmann, Jens, Lutz, Manfred B., Ip, Chi Wang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805693/ https://www.ncbi.nlm.nih.gov/pubmed/36587195 http://dx.doi.org/10.1186/s12974-022-02685-7

Ejemplares similares

Brain-to-gut trafficking of alpha-synuclein by CD11c(+) cells in a mouse model of Parkinson’s disease
por: McFleder, Rhonda L., et al.
Publicado: (2023)

Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α‐synuclein Parkinson's disease rat model
por: Musacchio, Thomas, et al.
Publicado: (2017)

Neuroinflammation in Parkinson’s Disease – Putative Pathomechanisms and Targets for Disease-Modification
por: Grotemeyer, Alexander, et al.
Publicado: (2022)

Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson’s disease
por: Grotemeyer, Alexander, et al.
Publicado: (2023)

Progressive Neurodegeneration or Endogenous Compensation in an Animal Model of Parkinson's Disease Produced by Decreasing Doses of Alpha-Synuclein
por: Koprich, James B., et al.
Publicado: (2011)

Rapid Regulatory T-Cell Response Prevents Cytokine Storm in CD28 Superagonist Treated Mice
por: Gogishvili, Tea, et al.
Publicado: (2009)

Topological Requirements and Signaling Properties of T Cell–activating, Anti-CD28 Antibody Superagonists
por: Lühder, Fred, et al.
Publicado: (2003)

AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson’s disease
por: Ip, Chi Wang, et al.
Publicado: (2017)

Self-Recognition Sensitizes Mouse and Human Regulatory T Cells to Low-Dose CD28 Superagonist Stimulation
por: Langenhorst, Daniela, et al.
Publicado: (2018)

Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis
por: Beyersdorf, Niklas, et al.
Publicado: (2005)

GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson’s Disease
por: Schneider, Jay S., et al.
Publicado: (2019)

CD28 Superagonist Shock and Blockage of Motogenic T Cell Cascade
por: Sundqvist, Karl-Gösta
Publicado: (2021)

CD28 superagonist-mediated boost of regulatory T cells increases thrombo-inflammation and ischemic neurodegeneration during the acute phase of experimental stroke
por: Schuhmann, Michael K, et al.
Publicado: (2015)

Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease
por: Koprich, James B, et al.
Publicado: (2010)

Non-steric-zipper models for pathogenic α-synuclein conformers
por: Schuman, Brock, et al.
Publicado: (2018)

Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson’s Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque
por: Koprich, James B., et al.
Publicado: (2016)

Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies
por: Waibler, Zoe, et al.
Publicado: (2008)

Superagonistic CD28 protects against renal ischemia injury induced fibrosis through a regulatory T-cell expansion dependent mechanism
por: Liang, Yiran, et al.
Publicado: (2019)

Tor1a+/- mice develop dystonia-like movements via a striatal dopaminergic dysregulation triggered by peripheral nerve injury
por: Ip, Chi Wang, et al.
Publicado: (2016)

A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson’s disease-like pathology in neurons and glia
por: Henrich, Martin Timo, et al.
Publicado: (2018)

CD28 Superagonistic Activation of T Cells Induces a Tumor Cell-Like Metabolic Program
por: Thaventhiran, Thilipan, et al.
Publicado: (2019)

Are there superagonists for calcium-activated potassium channels?
por: Brown, Brandon M., et al.
Publicado: (2017)

Revisiting CD28 Superagonist TGN1412 as Potential Therapeutic for Pediatric B Cell Leukemia: A Review
por: Brown, Katelyn E.
Publicado: (2018)

α-Synuclein–induced Kv4 channelopathy in mouse vagal motoneurons drives nonmotor parkinsonian symptoms
por: Chiu, Wei-Hua, et al.
Publicado: (2021)

Alpha Synuclein: Neurodegeneration and Inflammation
por: Forloni, Gianluigi
Publicado: (2023)

Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein
por: McKinnon, Chris, et al.
Publicado: (2020)

Exosome markers of LRRK2 kinase inhibition
por: Wang, Shijie, et al.
Publicado: (2020)

Inhibition of ZAP-70 Kinase Activity via an Analog-sensitive Allele Blocks T Cell Receptor and CD28 Superagonist Signaling
por: Levin, Susan E., et al.
Publicado: (2008)

Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonist
por: Thaventhiran, Thilipan, et al.
Publicado: (2014)

Combinations of anti-GITR antibody and CD28 superagonist induce permanent allograft acceptance by generating type 1 regulatory T cells
por: Que, Weitao, et al.
Publicado: (2022)

CITN-06: a Phase I/expansion trial of alt-803, an IL-15 superagonist, in patients with advanced melanoma
por: Margolin, Kim, et al.
Publicado: (2014)

Alpha-synuclein and tau: teammates in neurodegeneration?
por: Moussaud, Simon, et al.
Publicado: (2014)

Neurodegeneration and the ordered assembly of α-synuclein
por: Spillantini, Maria Grazia, et al.
Publicado: (2017)

Generation of a novel fully human non-superagonistic anti-CD28 antibody with efficient and safe T-cell co-stimulation properties
por: Elsayed, Abdullah, et al.
Publicado: (2023)

Taltirelin is a superagonist at the human thyrotropin-releasing hormone receptor
por: Thirunarayanan, Nanthakumar, et al.
Publicado: (2012)

New Roles for Vitamin D Superagonists: From COVID to Cancer
por: Easty, David J., et al.
Publicado: (2021)

Interactions between Calcium and Alpha-Synuclein in Neurodegeneration
por: Rcom-H’cheo-Gauthier, Alex, et al.
Publicado: (2014)

Mu-opioid receptor selective superagonists produce prolonged respiratory depression
por: Malcolm, Nicholas J., et al.
Publicado: (2023)

α-Synuclein Immunotherapy Blocks Uptake and Templated Propagation of Misfolded α-Synuclein and Neurodegeneration
por: Tran, Hien T., et al.
Publicado: (2014)

CD28 co-stimulation in T-cell homeostasis: a recent perspective
por: Beyersdorf, Niklas, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_pkjghtrt6lh8vegu61v19mcej2